Lucy

GMEX ZERO13 Collaborates with HyperloopTT's Innovation Management Platform "Lucy" for Sustainable Innovation

Retrieved on: 
Thursday, November 9, 2023

This collaboration marks a significant step toward fostering innovation that drives sustainability and positive environmental impact.

Key Points: 
  • This collaboration marks a significant step toward fostering innovation that drives sustainability and positive environmental impact.
  • The CEO of ZERO13 and GMEX Group, Mr. Hirander Misra, and HyperloopTT Group's Chief Labs Officer, Mr. Mauro Romano, have come together with a shared vision.
  • By combining Lucy's innovation lifecycle management solution and ZERO13's advanced carbon exchange ecosystem, these two innovative companies will create a holistic innovation management cycle to sustainability.
  • Together, HyperloopTT's Lucy and ZERO13 will play a pivotal role in shaping a sustainable future through innovative solutions.

Chesapeake Reports a New Gold Discovery at Lucy Project, Drilling Returned 6.1 g/t Gold over 24 Metres from Surface

Retrieved on: 
Tuesday, October 3, 2023

Lucy was staked by Chesapeake in 2017, and the initial exploration found zinc-bearing skarns to the Northwest ( See press release dated June 21, 2018 ).

Key Points: 
  • Lucy was staked by Chesapeake in 2017, and the initial exploration found zinc-bearing skarns to the Northwest ( See press release dated June 21, 2018 ).
  • In June 2023, a 1,710 metre 14-hole HQ core drill program was initiated to test this gold-bearing skarn system.
  • Holes LU23-05 to LU23-14 were collared over the gold zone defined by trenching and channel sampling.
  • The eight holes discovered a northeast trending zone of skarn at least 500 metres in strike length with significant gold mineralization.

Lucy Scientific Discovery Inc. Announces Acquisition of BlueSky Wellness Inc. in All-Stock Transaction

Retrieved on: 
Tuesday, September 12, 2023

This transaction expands Lucy’s footprint into the growing global wellness category by adding psychotropic products to its capabilities.

Key Points: 
  • This transaction expands Lucy’s footprint into the growing global wellness category by adding psychotropic products to its capabilities.
  • BlueSky Wellness is a portfolio of plant-based wellness brands including Keoni, Keoni Sport, Blush Wellness and AMMA Healing.
  • Richard Nanula, CEO of Lucy Scientific Discovery Inc., expressed his enthusiasm for the acquisition, stating, "The addition of the BlueSky portfolio and its team allows us to capitalize on revenue opportunities.
  • Lucy expects to complete the acquisition within 90 days, and will work closely with the BlueSky team during the transition.

Lucy® Advances Practical Generative AI for the Enterprise with Updates to Lucy Synopsis℠ Feature

Retrieved on: 
Tuesday, July 25, 2023

Lucy® , the world’s leading AI-powered Answer EngineSM, today announces eleven updates to its Lucy SynopsisSM feature.

Key Points: 
  • Lucy® , the world’s leading AI-powered Answer EngineSM, today announces eleven updates to its Lucy SynopsisSM feature.
  • Lucy provides in-line citations to source data, linking to the exact page of the content the answer was generated from.
  • All answers delivered through Lucy Synopsis are derived only from an enterprise’s internal documents and connected tools.
  • “The practical applications of generative AI for the enterprise are extremely compelling.

Lucy Scientific Discovery, Inc. Achieves Major Milestone with Successful Completion of its Acquisition of the Assets of Wesana Health

Retrieved on: 
Wednesday, July 5, 2023

VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. ("Lucy" or "the Company") (NASDAQ: LSDI) proudly announces the successful completion of its acquisition of Wesana Health Inc.'s ("Wesana") SANA-013 assets, marking a significant milestone in the field of mental health therapeutics.

Key Points: 
  • VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. ("Lucy" or "the Company") (NASDAQ: LSDI) proudly announces the successful completion of its acquisition of Wesana Health Inc.'s ("Wesana") SANA-013 assets, marking a significant milestone in the field of mental health therapeutics.
  • This acquisition strengthens Lucy's position as a leader in innovative drug development research and accelerates the development and commercialization of this groundbreaking treatment.
  • SANA-013 is being developed for the treatment of several mental health and central nervous system (CNS) related conditions, including Major Depressive Disorder (MDD), Migraine, Episodic Cluster Headaches, and Trigeminal Neuralgia (TG).
  • “I am pleased to announce the sale of our highly anticipated drug development program, SANA-013, to Lucy Scientific Discovery,” said Daniel Carcillo, Wesana founder and Chief Executive Officer.

Lucy Scientific Discovery to Present at the LD Micro Invitational XIII Conference on June 7

Retrieved on: 
Tuesday, June 6, 2023

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a leader in natural and synthetic psychedelic drug development, today announced that management is scheduled to participate in the LD Micro Invitational XIII Conference at the Luxe Sunset Boulevard Hotel in Los Angeles, CA on June 7, 2023.

Key Points: 
  • VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a leader in natural and synthetic psychedelic drug development, today announced that management is scheduled to participate in the LD Micro Invitational XIII Conference at the Luxe Sunset Boulevard Hotel in Los Angeles, CA on June 7, 2023.
  • The Company will host one-on-one investor meetings and is scheduled to present on Wednesday, June 7 at 9:30 am PT / 12:30 pm ET.
  • Interested parties are invited to register to watch the livestream of the conference including the Lucy presentation virtually here: https://ldinv13.sequireevents.com .

Lucy® Selected for SAP.iO Foundry B2B Innovation Program

Retrieved on: 
Tuesday, May 23, 2023

Lucy ®, the world's leading AI-powered Answer EngineSM, announces today its selection to the SAP.iO Foundry San Francisco Innovation in B2B Sales and Service program.

Key Points: 
  • Lucy ®, the world's leading AI-powered Answer EngineSM, announces today its selection to the SAP.iO Foundry San Francisco Innovation in B2B Sales and Service program.
  • Lucy was one of 11 companies selected by a jury of SAP experts, partners, customers, and investment funds to join the cohort.
  • “We are thrilled to join the SAP.iO Foundry San Francisco program.
  • She equips teams with the information they need in the moment to do their jobs and make better decisions faster.

Record-Breaking Comedians Gabriel “Fluffy” Iglesias and Taylor Tomlinson Headline National Comedy Center’s 2023 Lucille Ball Comedy Festival

Retrieved on: 
Friday, May 5, 2023

The National Comedy Center , the nation’s official museum and cultural institution dedicated to comedy, announced today that comedians Gabriel “Fluffy” Iglesias and Taylor Tomlinson will headline the 2023 Lucille Ball Comedy Festival , August 2 through 6.

Key Points: 
  • The National Comedy Center , the nation’s official museum and cultural institution dedicated to comedy, announced today that comedians Gabriel “Fluffy” Iglesias and Taylor Tomlinson will headline the 2023 Lucille Ball Comedy Festival , August 2 through 6.
  • Iglesias is the star and executive producer of the Netflix original comedy series Mr. Iglesias and numerous Netflix stand-up specials.
  • "I’m so excited to be a part of this summer’s Lucille Ball Comedy Festival in Jamestown, NY!” stated Taylor Tomlinson.
  • “It’s fitting that National Comedy Center’s festival will be headlined by both a legend of, and the future of, comedy.

Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, March 29, 2023

Lucy Therapeutics, Inc. , a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of Christopher J. Winrow, Ph.D., a neuroscience and translational medicine expert, as Chief Scientific Officer.

Key Points: 
  • Lucy Therapeutics, Inc. , a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of Christopher J. Winrow, Ph.D., a neuroscience and translational medicine expert, as Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230329005245/en/
    Lucy Therapeutics appoints Chief Scientific Officer Christopher J. Winrow, Ph.D. (Photo: Business Wire)
    At Lucy Therapeutics, Dr. Winrow will direct drug discovery and development strategy to advance the company’s promising pipeline, particularly its proprietary preclinical compounds in Parkinson’s disease, Rett syndrome, as well as other diseases of mitochondrial dysfunction.
  • He also will lead the development of scientific collaborations and partnerships to expand and optimize Lucy Therapeutics’ portfolio.
  • Before joining Lucy Therapeutics, Dr. Winrow was Vice President and Head of translational medicine at Cyclerion Therapeutics, a clinical-stage biopharmaceutical company focused on drug development for serious CNS diseases.

UNISTELLAR INTRODUCES EQUINOX 2 SMART TELESCOPE

Retrieved on: 
Wednesday, January 4, 2023

LAS VEGAS, January 4, 2023 /PRNewswire/ -- Unistellar, the creator of the world's most powerful and easy-to-operate smart telescopes, introduced the all-new eQuinox 2 at CES today. With the eQuinox 2, even users in light polluted cities and suburbs can now witness Jupiter's great red spot, the beautiful pink and purple colors of the Orion Nebula, our nearest stellar nursery, and the Whirlpool Galaxy colliding with a smaller nearby galaxy.

Key Points: 
  • LAS VEGAS, January 4, 2023 /PRNewswire/ -- Unistellar, the creator of the world's most powerful and easy-to-operate smart telescopes, introduced the all-new eQuinox 2 at CES today.
  • With the eQuinox 2, even telescope novices can find themselves observing astronomical phenomena in minutes thanks to a smart telescope 100 percent controlled by a mobile or tablet application.
  • The eQuinox 2 smart telescope will retail for $2,499, with pre-sales starting January 3 and global availability early 2023.
  • Unistellar is the creator of the world's most powerful and easy-to-operate smart telescopes, the eVscope 2 and the eQuinox 2.